Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Overexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node-positive breast cancer patients.

Yin X, Kim RH, Sun G, Miller JK, Li BD.

J Am Coll Surg. 2014 Apr;218(4):663-71. doi: 10.1016/j.jamcollsurg.2013.12.020. Epub 2014 Jan 4.

PMID:
24491247
[PubMed - indexed for MEDLINE]
2.

A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.

McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald JC, Abreo F, Li BD.

Ann Surg. 2005 Oct;242(4):584-90; discussion 590-2.

PMID:
16192819
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.

Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J, Meschonat C, Md QC, Li BD.

Ann Surg Oncol. 2008 Nov;15(11):3207-15. doi: 10.1245/s10434-008-0086-9. Epub 2008 Aug 22.

PMID:
18719964
[PubMed - indexed for MEDLINE]
4.

Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.

Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M, Li BD.

Surgery. 2009 Aug;146(2):220-6. doi: 10.1016/j.surg.2009.05.010.

PMID:
19628077
[PubMed - indexed for MEDLINE]
5.

Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.

Wolfort R, de Benedetti A, Nuthalapaty S, Yu H, Chu QD, Li BD.

Surgery. 2006 Aug;140(2):161-9.

PMID:
16904965
[PubMed - indexed for MEDLINE]
6.

Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.

Byrnes KW, DeBenedetti A, Holm NT, Luke J, Nunez J, Chu QD, Meschonat C, Abreo F, Johnson LW, Li BD.

J Am Coll Surg. 2007 May;204(5):925-33; discussion 933-4.

PMID:
17481512
[PubMed - indexed for MEDLINE]
7.

Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome.

Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, Nawas S, McDonald JC, DeBenedetti A.

Ann Surg. 2002 May;235(5):732-8; discussion 738-9.

PMID:
11981220
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

High eIF4E, VEGF, and microvessel density in stage I to III breast cancer.

Byrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson LW, Debenedetti A, Abreo F, Turnage RH, McDonald JC, Li BD.

Ann Surg. 2006 May;243(5):684-90; discussion 691-2.

PMID:
16633004
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

TLK1B is elevated with eIF4E overexpression in breast cancer.

Norton KS, McClusky D, Sen S, Yu H, Meschonat C, Debenedetti A, Li BD.

J Surg Res. 2004 Jan;116(1):98-103.

PMID:
14732354
[PubMed - indexed for MEDLINE]
10.

Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression.

Li BD, McDonald JC, Nassar R, De Benedetti A.

Ann Surg. 1998 May;227(5):756-6l; discussion 761-3.

PMID:
9605667
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma.

Li BD, Liu L, Dawson M, De Benedetti A.

Cancer. 1997 Jun 15;79(12):2385-90.

PMID:
9191527
[PubMed - indexed for MEDLINE]
12.

Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer.

Hiller DJ, Chu Q, Meschonat C, Panu L, Burton G, Li BD.

J Surg Res. 2009 Oct;156(2):265-9. doi: 10.1016/j.jss.2009.03.060. Epub 2009 May 3.

PMID:
19665145
[PubMed - indexed for MEDLINE]
13.

Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.

Zhou S, Wang GP, Liu C, Zhou M.

BMC Cancer. 2006 Sep 30;6:231.

PMID:
17010208
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome.

Chen CN, Hsieh FJ, Cheng YM, Lee PH, Chang KJ.

J Surg Oncol. 2004 Apr 1;86(1):22-7.

PMID:
15048676
[PubMed - indexed for MEDLINE]
15.

Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

Heikkinen T, Korpela T, Fagerholm R, Khan S, Aittomäki K, Heikkilä P, Blomqvist C, Carpén O, Nevanlinna H.

Breast Cancer Res Treat. 2013 Aug;141(1):79-88. doi: 10.1007/s10549-013-2671-2. Epub 2013 Aug 24.

PMID:
23974830
[PubMed - indexed for MEDLINE]
16.

Analysis of eIF4E and 4EBP1 mRNAs in head and neck cancer.

Sunavala-Dossabhoy G, Palaniyandi S, Clark C, Nathan CO, Abreo FW, Caldito G.

Laryngoscope. 2011 Oct;121(10):2136-41. doi: 10.1002/lary.22144. Epub 2011 Sep 6.

PMID:
21898433
[PubMed - indexed for MEDLINE]
17.

High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.

Chu QD, Panu L, Holm NT, Li BD, Johnson LW, Zhang S.

J Surg Res. 2010 Apr;159(2):689-95. doi: 10.1016/j.jss.2008.09.020. Epub 2008 Oct 16.

PMID:
19500800
[PubMed - indexed for MEDLINE]
18.

Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.

Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen LB.

Lung Cancer. 2009 Nov;66(2):237-44. doi: 10.1016/j.lungcan.2009.02.001. Epub 2009 Mar 3.

PMID:
19261348
[PubMed - indexed for MEDLINE]
19.

Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.

Sorrells DL, Meschonat C, Black D, Li BD.

J Surg Res. 1999 Jul;85(1):37-42.

PMID:
10383835
[PubMed - indexed for MEDLINE]
20.

Detection of eIF4E gene amplification in breast cancer by competitive PCR.

Sorrells DL, Black DR, Meschonat C, Rhoads R, De Benedetti A, Gao M, Williams BJ, Li BD.

Ann Surg Oncol. 1998 Apr-May;5(3):232-7.

PMID:
9607624
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk